GlaxoSmithKline Plc Valuation
| GSKN Stock | MXN 739.40 0.57 0.08% |
At this time, the firm appears to be fairly valued. GlaxoSmithKline plc retains a regular Real Value of 727.71 per share. The prevalent price of the firm is 739.4. Our model calculates the value of GlaxoSmithKline plc from evaluating the firm fundamentals such as return on asset of 0.0659, and Return On Equity of 0.31 as well as inspecting its technical indicators and probability of bankruptcy.
Fairly Valued
Today
Please note that GlaxoSmithKline Plc's price fluctuation is very steady at this time. Calculation of the real value of GlaxoSmithKline plc is based on 3 months time horizon. Increasing GlaxoSmithKline Plc's time horizon generally increases the accuracy of value calculation and significantly improves the predictive power of the methodology used.
Since GlaxoSmithKline Plc is currently traded on the exchange, buyers and sellers on that exchange determine the market value of GlaxoSmithKline Stock. However, GlaxoSmithKline Plc's intrinsic value may or may not be the same as its current market price, in which case there is an opportunity to profit from the mispricing, assuming the market price will eventually merge with its intrinsic value. | Historical | Market 739.4 | Real 727.71 | Hype 739.4 | Naive 753.08 |
The intrinsic value of GlaxoSmithKline Plc's stock can be calculated using various methods such as discounted cash flow analysis, price-to-earnings ratio, or price-to-book ratio. That value may differ from its current market price, which is determined by supply and demand factors such as investor sentiment, market trends, news, and other external factors that may influence GlaxoSmithKline Plc's stock price. It is important to note that the real value of any stock may change over time based on changes in the company's performance.
Estimating the potential upside or downside of GlaxoSmithKline plc helps investors to forecast how GlaxoSmithKline stock's addition to their portfolios will impact the overall performance. We also use other valuation drivers to help us estimate the true value of GlaxoSmithKline Plc more accurately as focusing exclusively on GlaxoSmithKline Plc's fundamentals will not take into account other important factors: GlaxoSmithKline Plc Total Value Analysis
GlaxoSmithKline plc is currently anticipated to have takeover price of 1.79 T with market capitalization of 1.38 T, debt of 19.76 B, and cash on hands of 6.53 B. Please note that takeover price may be misleading and is a subject to mistakes in financial statements. We encourage investors to thoroughly investigate all of the GlaxoSmithKline Plc fundamentals before making investing decisions based on enterprise value of the company| Takeover Price | Market Cap | Debt Obligations | Cash |
1.79 T | 1.38 T | 19.76 B | 6.53 B |
GlaxoSmithKline Plc Investor Information
About 14.0% of the company shares are owned by institutional investors. The company has Price/Earnings To Growth (PEG) ratio of 1.04. GlaxoSmithKline plc recorded earning per share (EPS) of 49.71. The entity last dividend was issued on the 23rd of February 2023. The firm had 4:5 split on the 22nd of July 2022. Based on the measurements of operating efficiency obtained from GlaxoSmithKline Plc's historical financial statements, GlaxoSmithKline plc is not in a good financial situation at the moment. It has a very high risk of going through financial straits in January.GlaxoSmithKline Plc Asset Utilization
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. GlaxoSmithKline Plc has an asset utilization ratio of 48.75 percent. This suggests that the Company is making 0.49 for each dollar of assets. An increasing asset utilization means that GlaxoSmithKline plc is more efficient with each dollar of assets it utilizes for everyday operations.GlaxoSmithKline Plc Ownership Allocation
GlaxoSmithKline plc has a total of 2.05 Billion outstanding shares. Roughly 85.88 (percent) of GlaxoSmithKline Plc outstanding shares are held by general public with 0.02 % owned by insiders and only 14.1 pct. by outside corporations. Please note that no matter how many assets the company holds, if the real value of the firm is less than the current market value, you may not be able to make money on it.GlaxoSmithKline Plc Profitability Analysis
The company reported the revenue of 29.32 B. Net Income was 14.96 B with profit before overhead, payroll, taxes, and interest of 19.92 B.About GlaxoSmithKline Plc Valuation
Our relative valuation model uses a comparative analysis of GlaxoSmithKline Plc. We calculate exposure to GlaxoSmithKline Plc's market risk, different technical and fundamental indicators, and relevant financial multiples and ratios and then compare them to those of GlaxoSmithKline Plc's related companies.GSK plc, together with its subsidiaries, engages in the creation, discovery, development, manufacture, and marketing of pharmaceutical products, vaccines, over-the-counter medicines, and health-related consumer products in the United Kingdom, the United States, and internationally. GSK plc was founded in 1715 and is headquartered in Brentford, the United Kingdom. GLAXOSMITHKLINE is traded on Mexico Stock Exchange in Mexico.
8 Steps to conduct GlaxoSmithKline Plc's Valuation Analysis
Company's valuation is the process of determining the worth of any company in monetary terms. It estimates GlaxoSmithKline Plc's potential worth based on factors such as financial performance, market conditions, growth prospects, and overall economic environment. The result of company valuation is a single number representing a Company's current market value. This value can be used as a benchmark for various financial transactions such as mergers and acquisitions, initial public offerings (IPOs), or private equity investments. To conduct GlaxoSmithKline Plc's valuation analysis, follow these 8 steps:- Gather financial information: Obtain GlaxoSmithKline Plc's financial statements, including balance sheets, income statements, and cash flow statements.
- Determine GlaxoSmithKline Plc's revenue streams: Identify GlaxoSmithKline Plc's primary sources of revenue, including products or services offered, target markets, and pricing strategies.
- Analyze market data: Research GlaxoSmithKline Plc's industry and market trends, including the size of the market, growth rate, and competition.
- Establish GlaxoSmithKline Plc's growth potential: Evaluate GlaxoSmithKline Plc's management, business model, and growth potential.
- Determine GlaxoSmithKline Plc's financial performance: Analyze its financial statements to assess its historical performance and future potential.
- Choose a valuation method: Consider the Company's specific circumstances and choose an appropriate valuation method, such as the discounted cash flow (DCF) or comparable analysis method.
- Calculate the value: Apply the chosen valuation method to the financial information and market data to calculate GlaxoSmithKline Plc's estimated value.
- Review and adjust: Review the results and make necessary adjustments, considering any relevant factors that may have been missed or overlooked.
Additional Tools for GlaxoSmithKline Stock Analysis
When running GlaxoSmithKline Plc's price analysis, check to measure GlaxoSmithKline Plc's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy GlaxoSmithKline Plc is operating at the current time. Most of GlaxoSmithKline Plc's value examination focuses on studying past and present price action to predict the probability of GlaxoSmithKline Plc's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move GlaxoSmithKline Plc's price. Additionally, you may evaluate how the addition of GlaxoSmithKline Plc to your portfolios can decrease your overall portfolio volatility.